Please register for Human Organs on Chips
July 20, 2017
2:00 PM EDT
Anthony Bahinski, PhD, MBA, FAHA
GlaxoSmithKline, King of Prussia, PA, United States
Development of safe and effective drugs is currently hampered by the poor
predictive power of existing preclinical animal models that often lead to
failure of drug compounds late in their development. Given the tremendous cost
of drug development and the long timelines involved, major pharmaceutical
companies and government funding agencies are now beginning to recognize a
crucial need for new technologies that can quickly and reliably predict drug
safety and efficacy in humans in preclinical studies. Advances in
bioengineering, material sciences, microfabrication, and microfluidics
technologies have enabled the development of microphysiological systems that
mimic the functional units of an organ. Organs-on-Chips are microfluidic cell
culture devices that contain hollow micrometer-sized chambers inhabited by
living cells that recreate the specialized multicellular architectures,
tissue-tissue interfaces, physicochemical microenvironments and vascular
perfusion necessary to recapitulate organ-level physiology in vitro. Combined
with the use of individual patient derived primary, or iPS-derived cells these
systems hold promise for the development of more translational disease models
and application in precision medicine and personalized health. These
microsystems could potentially further our understanding of disease etiology
and fill the critical need for improved model systems to predict efficacy,
safety, bioavailability, and toxicology outcomes for candidate compounds.
After registering, you will receive a confirmation email containing information
about joining the webinar.
All webinars are free and open to all, but advanced registration is required.
ASCCT members are able to access registration 1 week before the general public,
and are also able to access a library of video recordings of past webinars.
Please send questions to ksullivan@xxxxxxxx<mailto:ksullivan@xxxxxxxx>.